Data as of Nov 26
| +0.59 / +1.86%|
Impax Laboratories, Inc. is a technology-based specialty pharmaceutical company. It applies formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. The company operates its business through two reportable divisions: Global and Impax. The Global Division is focused on developing, manufacturing, selling and distributing controlled-release generic versions of selected brand-name pharmaceuticals covering a broad range of therapeutic areas and having technically challenging drug-delivery mechanisms or unique product development formulations. The Impax Division is focused on developing proprietary branded pharmaceutical products for the treatment of CNS disorders, which include epilepsy, migraine, multiple sclerosis and Parkinson's disease, and the promotion of branded pharmaceutical products through its specialty sales force. Impax Laboratories was founded on December 14, 1999 and is headquartered in Hayward, CA.
|George Frederick Wilkinson||President, Chief Executive Officer & Director|
|Bryan M. Reasons||Chief Financial Officer & Senior VP-Finance|
|Mark A. Schlossberg||Secretary, Senior Vice President & General Counsel|
|Michael J. Nestor||President-Impax Pharmaceuticals Division|
|Jeffrey D. Nornhold||Senior Vice President-Technical Operations|